New Peer-Reviewed Study Shows Ivermectin ‘Significantly’ Reduces COVID Infections, Hospitalization, and Mortality

Who could’ve seen this coming?

A newly released study from Brazil of over 150 thousand subjects found that regular prophylactic use of ivermectin “was associated with significantly reduced COVID-19 infection, hospitalization, and mortality rates.”

The largest ivermectin study to date was conducted in Itajaí, Brazil, between July 2020 and December 2020. It recently passed rigorous peer-review and was published this week, Dr. Pierre Kory noted on Twitter.

Background: Ivermectin has demonstrated different mechanisms of action that potentially protect from both coronavirus disease 2019 (COVID-19) infection and COVID-19-related comorbidities. Based on the studies suggesting efficacy in prophylaxis combined with the known safety profile of ivermectin, a citywide prevention program using ivermectin for COVID-19 was implemented in Itajaí, a southern city in Brazil in the state of Santa Catarina. The objective of this study was to evaluate the impact of regular ivermectin use on subsequent COVID-19 infection and mortality rates.

Researchers invited the entire population of Itajaí to enroll in the program and compiled baseline, personal, demographic, and medical information on participants.

In the absence of contraindications, ivermectin was offered as an optional treatment to be taken for two consecutive days every 15 days at a dose of 0.2 mg/kg/day. In cases where a participating citizen of Itajaí became ill with COVID-19, they were recommended not to use ivermectin or any other medication in early outpatient treatment. Clinical outcomes of infection, hospitalization, and death were automatically reported and entered into the registry in real time. Study analysis consisted of comparing ivermectin users with non-users using cohorts of infected patients propensity score-matched by age, sex, and comorbidities. COVID-19 infection and mortality rates were analyzed with and without the use of propensity score matching (PSM).

The results showed a 6.6 percent infection rate for non-users of ivermectin, and a 3.7 percent infection rate for regular users of the drug, a 44 percent reduction in the COVID-19 infection rate.

There was also a 56 percent reduction in the hospitalization rate for ivermectin users (44 versus 99 hospitalizations).

Continue reading>>>